Phase II trial of vepoloxamer (MST-188) in patients with acute decompensated heart failure

Trial Profile

Phase II trial of vepoloxamer (MST-188) in patients with acute decompensated heart failure

Planning
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Poloxamer 188 (Primary)
  • Indications Acute heart failure; Decompensated heart failure
  • Focus Biomarker; Therapeutic Use
  • Sponsors Mast Therapeutics; Savara Pharmaceuticals
  • Most Recent Events

    • 11 Feb 2015 According to a Mast Therapeutics media release, is planning to initiate this Phase 2 study in the second quarter of 2015
    • 09 Dec 2014 The US FDA has granted permission for the study to proceed, according to a Mast Therapeutics media release.
    • 24 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top